Company Encyclopedia
View More
name
TONGHUA GOLDEN-HORSE
000766.SZ
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China. Its products covers anti-tumor, microbial, cardiovascular, heat-clearing and detoxification, digestive system, skeletal muscle system, gynecological system, nervous system, and other fields. The company also provides bone peptides, protective chemical medicines, cardiovascular and cerebrovascular chinese patent medicines, heat-clearing and detoxifying medicines, and children's respiratory system chinese patent medicines; and Xiaojin pills, Tian Ranshexiang Xiaojin pills, Xiaokechuan capsules, Jiuwei Qianghuo granules, Xiongdan powder, Bear Bile powder, and Wenweishu tablets to treat glandular hyperplasia, inflammatory diseases, bone trauma and soft tissue injury, and other related diseases. In addition, the company offers bacillus cereus live bacteria capsules, bacillus cereus live bacteria tablets are therapeutic live bacteria microecological preparations to treat enteritis, diarrhea, infantile diarrhea, and intestinal dysfunction.
3.157 T
000766.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking84/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.48%C
    • Profit Margin4.61%C
    • Gross Margin70.66%A
  • Growth ScoreD
    • Revenue YoY-10.84%D
    • Net Profit YoY9.88%C
    • Total Assets YoY-1.53%D
    • Net Assets YoY-1.74%D
  • Cash ScoreC
    • Cash Flow Margin2168.20%A
    • OCF YoY-10.84%D
  • Operating ScoreD
    • Turnover0.27D
  • Debt ScoreC
    • Gearing Ratio49.17%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TONGHUA GOLDEN-HORSE released its performance for the first half of the year, with a net profit attributable to the parent company of 16.804 million yuan, a year-on-year increase of 34.77%

    TONGHUA GOLDEN-HORSE released its 2025 semi-annual report, with operating revenue of 650 million yuan, a year-on-year increase of 0.12%; net profit attributable to the parent company of 16.804 million yuan, a year-on-year increase of 34.77%; net profit excluding non-recurring gains and losses of 14.4073 million yuan, a year-on-year increase of 125.07%; basic earnings per share of 0.0174 yuan

    Zhitong·
    SZ
    000766
    +0.10%
    Zhitong·
    SZ
    000766
    +0.10%

    The chemical pharmaceutical sector has declined in the short term, with CSBIO falling over 12%

    The chemical pharmaceutical sector has seen a short-term decline, with CSBIO falling over 12%. YONGAN PHARMACEUTICAL, HYBIO, TONGHUA GOLDEN-HORSE, Cosunter, and others have also followed suit

    Zhitong·
    SZ
    002365
    +0.25%
    SZ
    300199
    +3.00%
    SZ
    000766
    +0.10%
    Zhitong·
    SZ
    002365
    +0.25%
    SZ
    300199
    +3.00%
    SZ
    000766
    +0.10%

    TONGHUA GOLDEN-HORSE: There are no significant matters that should be disclosed but have not been disclosed

    Tonghua Golden-Horse announced that the trading price of the company's stock has increased by more than 20% over three consecutive trading days, which constitutes an abnormal fluctuation. After verification, the company confirmed that there is no need to correct or supplement previously disclosed information, and no undisclosed significant information that may affect the stock price has been found. The company's operating conditions and internal and external environment have not undergone significant changes, and the controlling shareholder and actual controller have no significant matters that should be disclosed but have not been disclosed, and they have not bought or sold the company's stock during the period of abnormal stock fluctuation. The company's board of directors confirms that there are currently no matters or information that should be disclosed but have not been disclosed, and reminds investors to pay attention to risks

    Zhitong·
    SZ
    000766
    +0.10%
    Zhitong·
    SZ
    000766
    +0.10%

    Innovative drug concept stocks rise, Staidson BioPharm up over 10%

    Innovative drug concept stocks surged, Staidson BioPharm rose over 10%, Hinova rose over 6%, Hotgen, Hengrui Pharma, and TONGHUA GOLDEN-HORSE also saw increases

    Zhitong·
    SH
    688068
    -3.88%
    SH
    600276
    +0.60%
    SZ
    000766
    +0.10%
    Zhitong·
    SH
    688068
    -3.88%
    SH
    600276
    +0.60%
    SZ
    000766
    +0.10%

    TONGHUA GOLDEN-HORSE released its first-quarter performance, with a net profit attributable to the parent company of 11.5828 million yuan, a year-on-year increase of 26.09%

    According to the Zhitong Finance APP, TONGHUA GOLDEN-HORSE released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 299 million yuan, a year-on-year increase of 1.25%. The net profit attributable to shareholders of the listed company was 11.5828 million yuan, a year-on-year increase of 26.09%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 10.046 million yuan, a year-on-year increase of 58.53%

    Zhitong·
    SZ
    000766
    +0.10%
    Zhitong·
    SZ
    000766
    +0.10%
    © 2025 Longbridge｜Disclaimer